Product Description
Eluxadoline is a new therapeutic agent that reduced symptoms of IBS with diarrhea in men and women, with sustained efficacy over 6 months in patients who received the 100-mg dose twice daily. a new oral agent with mixed opioid effects (mu- and kappa-opioid receptor agonist and delta-opioid receptor antagonist) (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa1505180)
Mechanisms of Action: OPRD Antagonist,OPRK Agonist,OPRM Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Belgium | Canada | European Medicines Agency | Hungary | Ireland | Italy | Latvia | Lithuania | New Zealand | Poland | Portugal | Saudi Arabia | Spain | Sweden | United Kingdom | United States
Approved Indications: Irritable Bowel Syndrome | Diarrhea
Known Adverse Events: Abdominal Pain | Pain Unspecified | Constipation
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Canada, Hungary, Netherlands, Poland, United Kingdom, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Diarrhea|Irritable Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT04880876 | P3 |
Enrolling by invitation |
Irritable Bowel Syndrome|Diarrhea |
2027-03-15 |
41% |
| NCT03339128 | P2 |
Recruiting |
Irritable Bowel Syndrome|Diarrhea |
2026-12-14 |